Clinical Trial Update: Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immune response of a Tick-Borne Encephalitis vaccine (LGT(TP21)/DEN4) in healthy adults; study completed with results reporte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• LGT(TP21)/DEN4 Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Tick-Borne Encephalitis | Phase 1 | Status: COMPLETED